Norwegian Bladder and Urothelial Cancer Registry
The Norwegian Bladder and Urothelial Cancer Registry received national approval in 2024 and has produced an annual report based on generic data from the Cancer Registry’s core database.
The first annual report contains analyses of figures of a more descriptive nature, as the data is currently limited. The development of bladder and urothelial cancer-specific forms will, in time, provide an even more detailed description of the diagnosis and treatment of bladder and urothelial cancer, as well as adherence to the Action Program.
The Bladder Cancer Registry aims to enhance the quality of healthcare provided to patients with bladder and urothelial cancer. The registry will also support, promote, and provide a basis for research to develop new knowledge about the causes, diagnosis, disease progression, and treatment effects of this cancer.
Bladder cancer can significantly impact patients' quality of life. Over time, the collection of patient-reported outcomes (PROM) will provide insights into how bladder cancer patients in Norway are doing and the challenges they face.
Facts about bladder cancer on kreftregisteret.no
Registration to the register
In the coming year, a dedicated clinical report form for the diagnosis and treatment of bladder and urothelial cancer will be launched. The development of bladder- and urothelial cancer-specific forms will, over time, provide a more detailed description of the diagnosis and treatment of bladder and urothelial cancer, as well as adherence to the Action Program.
Coverage rate and data quality
Patient group
All patients with cancer of the urethra, bladder, ureter, and renal pelvis (ICD-10 C65-68), as well as D090, D091, and D41 (excluding D410), are included in the register.
Bladder cancer is treated with surgery, radiation therapy, chemotherapy, and immunotherapy.
Treating healthcare units
Bladder and urothelial cancer patients are diagnosed, treated, and followed up in both primary healthcare services and specialized healthcare services. All doctors providing medical care to cancer patients are required to report to the Cancer Registry. This includes reporting to the Norwegian Bladder and Urothelial Cancer Registry.
Bladder and urothelial cancer is diagnosed and/or treated at nearly all hospitals in the country, and these hospitals report to the Cancer Registry of Norway. Cystectomies and cystoprostatectomies are centralized.
Results (Norwegian only)
